Illumina Revenues Up
Illumina reported increased revenues for the first quarter last week, amid nearly flat net losses.
The San Diego genotyping and oligonucleotide company’s revenues for the quarter totaled $4.3 million, up from $1.3 million for the year-ago quarter. Net losses totaled $9.0 million, up from $8.7 million for the first quarter of 2002. Research and development expenses were $5.7 million, from $7.1 million in Q1 2002.
Â
Nanosys GET New Funders in $30M Series B
Nanosys of Palo Alto, Calif., last week announced new investors in the first closing of its $30 million Series B funding. The company’s new investors in an initial closing of funding include CDIB BioScience Ventures, Chiao Tung Bank, China Development Industrial Bank, Harris & Harris, Lux Capital, Quanta Computer, and SAIC Venture Capital Corp.
Â
Paradigm Gets $8.4M More in NIEHS Funding
Paradigm Genetics of Research Triangle Park, NC, will receive $8.4 million from the National Institute of Environmental Health Sciences for toxicogenomics studies, in addition to $23.8 million already funded under a five-year contract, the company said last week. The original contract calls for Paradigm researchers to use a gene-expression platform based on technology developed at Agilent Technologies to discern what happens to an organism when an undisclosed variety of toxicants, drugs, and pesticides have been introduced.
Some $2 million will go toward research for the National Toxicology Program.